罗格列酮用于多囊卵巢综合征促排卵治疗的效果观察

Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome

目的 探讨罗格列酮 (rosiglitazone)对存在胰岛素抵抗的多囊卵巢综合征 (polycysticovarysyndrome ,PCOS)患者促排卵治疗的效果。 方法 选择存在胰岛素抵抗的PCOS患者 96例 ,将其随机分为A、B、C组。A组 (2 8例 )口服氯米芬、B组 (3 2例 )口服罗格列酮、C组 (3 6例 )口服罗格列酮联合氯米芬 ,3组用药时间均为 3个月经周期。比较 3组用药前后的胰岛素抵抗指数的变化和排卵情况。结果 B组和C组患者治疗后 ,应用稳态模型评估的胰岛素抵抗指数 (homeostasismodelassessmentinsulinresistance ,HOMAIR)分别由 1 2± 0 6、1 1± 0 5下降为 0 6± 0 2、0 6± 0 4,两组治疗前后比较 ,差异也有显著性 (P <0 0 5)。C组治疗后排卵率为 80 % ,明显高于A组的 59%和B组的 3 5% ,差异有显著性 (P <0 0 5)。结论 罗格列酮能有效地改善胰岛素抵抗 。

ObjectiveTo investigate the effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome (PCOS) MethodsNinety-six PCOS women with insulin resistance (IR) were randomly divided into three groups Group A (28 cases) received clomiphene citrate (CC) alone Group B (32 cases) received rosiglitazone alone And group C (36 cases) received CC and rosiglitazone in combination All were treated for three menstrual cycles Homeostasis model assessment insulin resistance (HOMA IR) and ovulation before and after treatment were compared among the 3 groups ResultsAfter the treatment, HOMA IR in group B and C decreased from 1 2±0 6 to 0 6±0 2 and from 1 1±0 5 to 0 6±0 4, respectively (P<0 05) Success rate of ovulation after treatment in group C (80%) was higher than that in group A ( 59% ) and group B (35%, P <0 05) ConclusionRosiglitazone therapy improves insulin sensitivity and ovulation induction